This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

James G. Jollis, MD; Ross J. Simpson, Jr, MD, PhD; Mridul K. Chowdhury, PhD; Wayne E. Cascio, MD; John R. Crouse III, MD; Mark W. Massing, MD, MPH; Sidney C. Smith, Jr, MD

Arch Intern Med. 1999;159:2341-2348.

Background  Although calcium channel blockers are a useful therapy in relieving angina, lowering blood pressure, and slowing conduction of atrial fibrillation, growing evidence has cast doubt on their safety in patients with coronary disease.

Objective  To examine the association between calcium channel blocker therapy at hospital discharge and mortality in a population-based sample of elderly patients hospitalized with acute myocardial infarction.

Design  Retrospective cohort study using data from medical charts and administrative files.

Setting  All acute care hospitals in 46 states.

Patients  All Medicare patients with a principal diagnosis of acute myocardial infarction consecutively discharged from the hospital alive during 8-month periods between 1994 and 1995 (N = 141,041).

Main Outcome Measure  Mortality at 30 days and 1 year.

Results  Calcium channel blockers were widely prescribed at hospital discharge to elderly patients with myocardial infarction between 1994 and 1995 (n = 51,921), the most commonly prescribed being diltiazem (n = 21,175), nifedipine (n = 12,670), amlodipine (n = 11,683), and verapamil (n = 3639). After adjusting for illness severity and concomitant medication use, patients who were prescribed calcium channel blockers at hospital discharge did not have increased risk for 30-day or 1-year mortality, with the exception of the few (n = 116) treated with bepridil. Bepridil differs from other calcium channel blockers because of its tendency to prolong repolarization, and its association with proarrhythmic effects in elderly patients.

Conclusion  We did not identify a mortality risk in a large consecutive sample of elderly patients with myocardial infarction, which supports the need for additional prospective trials examining calcium channel blocker therapy for ischemic heart disease.

From the Duke Clinical Research Institute, Duke University, Durham, NC (Dr Jollis); Medical Review of North Carolina Inc, Cary (Drs Simpson and Chowdhury); Division of Cardiology (Drs Simpson, Cascio, and Smith) and Department of Epidemiology (Dr Massing), University of North Carolina, Chapel Hill; and the Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC (Dr Crouse).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 1999;159(19):2369-2370.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Volume-Outcome Relationship in Acute Myocardial Infarction: The Balloon and the Needle
Jollis and Romano
JAMA 2000;284:3169-3171.
FULL TEXT  

First line drugs in chronic stable effort angina--the case for newer, longer-acting calcium channel blocking agents
Opie
J Am Coll Cardiol 2000;36:1967-1971.
ABSTRACT | FULL TEXT